• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Fujifilm Holdings Corp.

Headquarters: Tokyo, Japan
Website: http://www.fujifilmholdings...
Year Founded: 1934
Status: Public
Industry Sector: HealthTechnology
CEO: Teiichi Goto
Number Of Employees: 72,254
Enterprise Value: $29,670,848,000
PE Ratio: 13.71
Exchange/Ticker 1: Tokyo:4901
Exchange/Ticker 2: N/A
Latest Market Cap: $24,156,539,813

BioCentury | Dec 13, 2023
Finance

Dec. 12 Quick Takes: Targeted genomic DNA insertion company Tome launches with $213M

Plus: Bicara’s latest big round is a $165M series C, Shinobi launches, Pfizer readies to close Seagen deal and more
Read More
BioCentury | Oct 14, 2022
Finance

Oct. 14 Quick Takes: Sofinnova Partners, Mérieux back French ADC company Mablink

Plus Enliven finds path to NASDAQ via Imara deal and updates from Reata, Travere, Fujifilm, Inotrem, Obatala
Read More
BioCentury | Mar 24, 2022
Deals

March 23 Quick Takes: FDA approves Novartis’ radiotherapy for prostate cancer

Plus Fujifilm buys a recombinant protein manufacturer, and updates from 4D pharma, Neurana and more
Read More
BioCentury | Feb 4, 2022
Finance

Weathering one of biotech’s worst bear markets

Investors prioritize cash, liquidity and management experience
Read More
BioCentury | Nov 16, 2021
Finance

Building cell therapy ‘family,’ PE-backed Kiniciti takes stake in Ncardia

With new investment from Biospring, Kiniciti aims to create portfolio of complementary cell therapy tools, technologies
Read More
BioCentury | Oct 1, 2021
Product Development

Data suggest Merck could be first in U.S. to gain EUA for oral antiviral

Molnupiravir readout in COVID adds $16B to pharma’s market cap, sinks shares of vaccine players
Read More
BioCentury | Jan 22, 2021
Product Development

Slaoui on Warp Speed’s successes, limitations and lessons

Operation Warp Speed’s co-leader describes how the U.S. government helped move COVID-19 vaccines across the finish line in record time
Read More
BioCentury | Dec 1, 2020
Product Development

U.K., South African data backup plan for Novavax in U.S.

U.S. Phase III trial delayed as leading vaccines near FDA authorization
Read More
BioCentury | Jul 31, 2020
Product Development

U.K. locks down access to recombinant protein vaccine via GSK, Sanofi deal, its fourth for COVID-19

Plus updates on Kodak, Akiko Iwasaki and Reata
Read More
BioCentury | Jul 31, 2020
Product Development

COVID-19 antibody treatments could be available in September, ahead of vaccines

Read More
Items per page:
1 - 10 of 103